Dure Nayab, Habibullah Khan, Hafsa Habib


Hepatitis C virus (HCV) infection is a global health problem. In Pakistan, more than 10 million people are suffering from HCV infection with an estimated prevalence of 4.9%. Hepatitis C virus is classified into six genotypes. Various genotypes respond differently to different treatment regimes. In Pakistan, 79% cases of HCV infections have genotype 3. The aim of therapy in chronic HCV infection is to attain sustained virologic response and thus reduce liver fibrosis and hepatoma. Although Interferon plus ribavirin therapy shows a good response in patients with genotype 3, yet the problem with this regimen is the serious side-effects of interferon. For these reasons interferon-free therapy was always a desire. Directly acting agents like sofosbuvir has made the dream of interferon-free therapy a reality. Studies have shown an excellent response to combination of sofosbuvir and ribavirin therapy in genotype 3 which is the most prevalent type in Pakistani population.


Chronic hepatitis C; Sofosbuvir; Interferon; Pakistan.

Full Text:



Farooqi JI, Alam A, Abbas Z, Naqvi AB, Zuberi BF, Nawaz AA, et al. Hep-net opinion about the management of patients with chronic hepatitis C in Pakistan in the era of available DAA. J Postgrad Med Inst 2016; 30:6-14.

Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and the possible routes of transmission. BMC Infect Dis 2008; 8:69.

Riaz S, Iqbal A. A review of hepatitis C in the general population in Pakistan. Viral Hepat J 2016; 220:74-81.

Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HU. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J 2010; 16:15-23.

Thompson AJ, Holmes JA. Treating hepatitis C - what’s new? Aust Presc 2015; 38:191-7.

Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J Gastroenterol 2009; 45:5647-53.

Safi SZ, Badshah Y, Waheed Y, Fatima K, Tahir S, Shinwari A, et al. Distribution of hepatitis C virus genotypes, hepatic steatosis and their correlation with clinical and virological factors in Pakistan. Asian Biomed 2010; 4:253-62.

Chinchai T, Labout J, Noppornpanth S, Theamboonlers A, Haagmans BL, Osterhaus AD, et al. Comparative study of different methods to genotype hepatitis C virus type 6 variants. J Virol Methods 2003; 109:195-201.

Dan YY, Lim Sc. Hepatitis C: an Eastern perspective. Gastroenterol Clin N Am 2015; 44:793-805.

Irfan M, Mohsin A, Nasir N, Aftab GM, Iram R, Batool S, et al. Factors influencing the response of sofosbuvir and ribavirin therapy in chronic hepatitis C patients in Punjab, Pakistan. IJSRM Human 2016; 4:217-24.

Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677-84.

Waheed Y. Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: treatment response, side effects and future prospective. Asian Pac J Trop Med 2015; 8:85-9.

Burki T. Elimination on the agenda for hepatitis C. Lancet 2014; 14:452-3.

Khokhar N. Hepatitis C treatment gets into a new gear. J Coll Phy Surg Pak 2014; 24:879-81.

Ahmad K. New era in hepatitis C therapy. J Islamabad Med Dent Coll 2014: 3:1-2.

Akhter TS, Umar M, Khaar H, Aslam F, Nisar G, Naseer A, et al. Sofosbuvir for the treatment of hepatitis C genotype 3 infected patients in Pakistan. J Ayub Med Coll Abbottabad 2017; 28 (Suppl 1):884-9.

Mansoor VB, Ahmed U, Jahanzaib M, Ali Z, Haroon MA, Ahmed H, et al. End treatment response in chronic hepatitis C patients to sofosbuvir and ribavirin. Ann Pak Inst Med Sci 2016; 12:127-30.

Aziz H, Raza A, Irfan J. Optimum predictors of therapeutic outcome in HCV patients in Pakistan. J Med Virol 2016; 88:100-8.

Hajarizadeh B. Generic direct acting antiviral treatment: the first step towards elimination of hepatitis C in Iran. Hepat Mon 2017;17:e45788.

Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.

World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Geneva, Switzerland: World Health Organization; 2016.

Feld JJ. The beginning of the end: what is the future of interferon therapy for chronic hepatitis C? Antiviral Res 2014; 105:32-8.

Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Stephen Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-31). Hepatology 2016; 63:1430-41.

Sohail AM. Hepatitis C virus and interferon-free antiviral therapeutics revolution: implications for Pakistan. Viral Immunol 2017;30:252-7.

Umar M, Akhter TS, Akbar I, Nisar G, Osama M. Role of generics in treatment of hepatitis c infection. J Ayub Med Coll Abbottabad 2016; 28:890–4.

Umar M, Akhter TS, Osama M. Issues pertaining to DAAs. J Ayub Med Coll Abbottabad 2016; 28:895-900.

Waheed Y. Ledipasvir and sofosbuvir: interferon free therapy for HCV genotype 1 infection. World J Virol 2015;4:33-5.

Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof of concept phase 2a cohort study. Lancet Infect Dis 2015; 15:1049–54.


  • There are currently no refbacks.

© 2011 Gomal Journal of Medical Sciences